M?rup SB, Milojevic M, Shahri SMT, Sherman BT, Cha. Investigating the Impact of Host Genetics on the Risk of Disease Progression in Individuals With Influenza. Immun Inflamm Dis. 2026 Mar;14(3):e70394
Background: Knowledge of the human genetic contribution to the risk of complications from influenza is limited. This study assessed the association between human single-nucleotide polymorphisms (SNPs) and disease progression in individuals with influenza.
Methods: A targeted analysis of 10 SNPs with prior evidence in COVID-19 and a genome-wide association study (GWAS) were used to assess associations between SNPs and disease progression in two multinational cohorts with suspected or laboratory-confirmed influenza: a hospitalized cohort (n = 1634) and a pooled cohort of hospitalized and outpatients (n = 3469). Disease progression was defined as prolonged hospitalization (> 28 days), progression to mechanical ventilation, admittance to intensive care unit, or death (for hospitalized individuals) or progression to hospitalization or death (for outpatients).
Results: Disease progression was observed in 9.1% of hospitalized patients and 2.2% of outpatients. Age was a significant risk factor for disease progression, with 20% increased odds of disease progression per 10-year increase in age (OR: 1.20, 95%CI: 1.08-1.33, p < 0.001). Disease progression rates also differed by continent (p < 0.0001). Targeted SNP analyses did not identify significant associations with disease progression; however, the strength of associations was most pronounced in sensitivity analyses for the pooled cohort in individuals < 65 years old. GWAS analyses did not identify significant common SNP associations in either the hospitalized or pooled cohorts, nor in sensitivity analysis of (1) individuals with laboratory-confirmed influenza and (2) those aged < 65 years.
Conclusion: In a geographically diverse cohort of individuals with influenza, the genetic links to disease progression only started to become evident in the sensitivity analyses, mainly when looking at younger individuals. The power to detect associations was limited by the rate of disease progression and heterogeneity in phenotypes of the individuals studied, and therefore, additional studies focused on the role of genetics in influenza disease progression are needed.
Methods: A targeted analysis of 10 SNPs with prior evidence in COVID-19 and a genome-wide association study (GWAS) were used to assess associations between SNPs and disease progression in two multinational cohorts with suspected or laboratory-confirmed influenza: a hospitalized cohort (n = 1634) and a pooled cohort of hospitalized and outpatients (n = 3469). Disease progression was defined as prolonged hospitalization (> 28 days), progression to mechanical ventilation, admittance to intensive care unit, or death (for hospitalized individuals) or progression to hospitalization or death (for outpatients).
Results: Disease progression was observed in 9.1% of hospitalized patients and 2.2% of outpatients. Age was a significant risk factor for disease progression, with 20% increased odds of disease progression per 10-year increase in age (OR: 1.20, 95%CI: 1.08-1.33, p < 0.001). Disease progression rates also differed by continent (p < 0.0001). Targeted SNP analyses did not identify significant associations with disease progression; however, the strength of associations was most pronounced in sensitivity analyses for the pooled cohort in individuals < 65 years old. GWAS analyses did not identify significant common SNP associations in either the hospitalized or pooled cohorts, nor in sensitivity analysis of (1) individuals with laboratory-confirmed influenza and (2) those aged < 65 years.
Conclusion: In a geographically diverse cohort of individuals with influenza, the genetic links to disease progression only started to become evident in the sensitivity analyses, mainly when looking at younger individuals. The power to detect associations was limited by the rate of disease progression and heterogeneity in phenotypes of the individuals studied, and therefore, additional studies focused on the role of genetics in influenza disease progression are needed.
See Also:
Latest articles in those days:
- Highly Pathogenic Avian Influenza A(H5N1) Virus RNA in Bovine Semen, California, USA, 2024 3 hours ago
- Rapid expansion of genotype D1.1A(H5N1) influenza viruses in wild birds across North America during the 2024 migratory season 4 hours ago
- Outbreak dynamics of high pathogenicity avian influenza virus H5N1, clade 2.3.4.4b euBB, in black-headed gulls and common terns in Germany in 2023 4 hours ago
- Population immunity to clade 2.3.4.4b H5N1 is dominated by anti-neuraminidase antibodies 4 hours ago
- Characterisation of immune responses targeting highly pathogenic avian influenza A(H5) viruses in health-care workers in the Netherlands: an observational, cross-sectional analysis 4 hours ago
[Go Top] [Close Window]


